{"id":414958,"date":"2021-01-14T09:03:35","date_gmt":"2021-01-14T14:03:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=414958"},"modified":"2021-01-14T09:03:35","modified_gmt":"2021-01-14T14:03:35","slug":"ceapro-inc-to-present-at-noblecon17","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/","title":{"rendered":"Ceapro Inc. to Present at NobleCon17"},"content":{"rendered":"<h2>\nLive video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">EDMONTON, Alberta, Jan.  14, 2021  (GLOBE NEWSWIRE) &#8212; <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OOuvj5hL1bcec9COJ_lVkz7U--CWsHdvwHT76PC9bOxzvHJYDmsJbMt3Y0q4sea7EFN3w8XXhgTOSg7CN6LYKA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Ceapro Inc.<\/u><\/a><\/strong>\u00a0<strong>(<\/strong><strong>TSX-V: CZO; OTCQX: CRPOF) (\u201cCeapro\u201d or the \u201cCompany\u201d)<\/strong>, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G2QjUlJ0mT1_loODGu-UE-_quvjQSCssxaRVJK2KHqYMgw9ymMLySn0ewkGy_dDt30OaoeqD3ObPcH43NVffGgiHnLD2DTB2uLxaXX5FovIRdAR8m7FZSDFz_R7L8tZS8WWle7L5Bu3Kba0XCXqedeLAbf0IqPW6Le-2QmBxgU4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Gilles Gagnon, President and Chief Executive Officer<\/u><\/a> of Ceapro will present at NobleCon17 &#8211; Noble Capital Markets\u2019 Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 11:15 AM ET.\u00a0<\/p>\n<p align=\"justify\">A high-definition, video webcast will be available at the time of the Company\u2019s presentation for those registered to attend the event. The conference is virtual, with no cost, obligation or restrictions to attend: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HIBU2bdgXR-bfBN1ndCu4AdRRaV11R9JUBeoEYuXVw6Aj3g46B7g78JNHk4_Aui-9cFkXScP6RLbsYcCQ_4zobDaT10p9hEPMi38lbZiu8kv2kI4XFe6H1jw6Tc8svFW\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.noblecon17.com<\/u><\/a>.<\/p>\n<p align=\"justify\">A <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=09YGx-f866MVXNoZ7QsjECLbYSZkwfOtxyAlauXqjTR4pVIOcyWviTjD8ITPUTnK-eIhXcfVN9f30UlalywlDAvnRWqwSGwcgUaLMFU6yEEKZfB_7HtwRqqNSJ5tydHxzbVRKyIen5B8tLYM4svB5GjBHrHWFXrKh_H51pHT8XE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>webcast replay<\/u><\/a> will be available approximately 24 hours following the presentation on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9NcA5H-Bz61ex6rYmPUDjHOaxGRRbeS3ljJLKG2Dq241LT-7j3PW53XsxYe9gwGgn3WB-x_GwfiHJmQkkxATZSWupx7nMudLLxWmBX11NkQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>IR Calendar<\/u><\/a> page of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dHPn9B2opLPiN3g44MnQq0FPVn4oDZnPlM6f_Hkec3gW61Nr9LAxfPzze3abpu6stdjpEQm70fw1Qfpr3x1sng==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Investors<\/u><\/a> section of the Company&#8217;s website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qqVTuB7KUbWq2LaPMoFyhAB4TjPFHoofF4wfhtlUvKImkYabseg1JmnUmp_fjMJwC3BiJTKG1uhscEhkLyU4Lg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.ceapro.com<\/u><\/a>), and as part of a complete catalog of presentations to be rebroadcast on Channelchek, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jvRlHvUfH7B_qzJfqizmQ1_tASsz3G6SY2OdMmtQOKPr1PaNdT5euq77GB_3fI5vLM37TI-H8ZcDjvRZWmchx353CHGZRbotAel2_TbxghA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.channelchek.com<\/u><\/a>, next month.<\/p>\n<p align=\"justify\">\n        <strong>About Ceapro Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and \u201cactive ingredients\u201d from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qqVTuB7KUbWq2LaPMoFyhAcXK15dU3SfmD9QKojlOabZMrX2Edp5w8DnT1a9Kik1J45sE-Cz1gl2lz0temv-hQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.ceapro.com<\/u><\/a>.<\/p>\n<p>\n        <strong>For more information contact:<\/strong>\n      <\/p>\n<p>Jenene Thomas<br \/>JTC Team, LLC<br \/>Investor Relations and Corporate Communications Advisor<br \/>T (US): +1 (833) 475-8247<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FtszMoxSjAhn4eh5mImA9-PuOPXx_cMlnA-DbhmT2CW30CC3rfArHGIpKpYNrfMrJNel5zt2yauYS4Z7SLi-HA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>czo@jtcir.com<\/u><\/a><\/p>\n<p> Issuer:<\/p>\n<p>Gilles R. Gagnon, M.Sc., MBA<br \/>President &amp; CEO<br \/>T: 780-421-4555<\/p>\n<p align=\"center\">\n        <em>Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release<\/em>\n      <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d72959fb-207e-4f69-8f2e-f103d8ad4519\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Live video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; Ceapro Inc.\u00a0(TSX-V: CZO; OTCQX: CRPOF) (\u201cCeapro\u201d or the \u201cCompany\u201d), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at NobleCon17 &#8211; Noble Capital Markets\u2019 Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 11:15 AM ET.\u00a0 A high-definition, video webcast will be available at the time of the Company\u2019s presentation for those registered to attend the event. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com. A &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ceapro Inc. to Present at NobleCon17&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-414958","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ceapro Inc. to Present at NobleCon17 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ceapro Inc. to Present at NobleCon17 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Live video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; Ceapro Inc.\u00a0(TSX-V: CZO; OTCQX: CRPOF) (\u201cCeapro\u201d or the \u201cCompany\u201d), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at NobleCon17 &#8211; Noble Capital Markets\u2019 Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 11:15 AM ET.\u00a0 A high-definition, video webcast will be available at the time of the Company\u2019s presentation for those registered to attend the event. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com. A &hellip; Continue reading &quot;Ceapro Inc. to Present at NobleCon17&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-14T14:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ceapro Inc. to Present at NobleCon17\",\"datePublished\":\"2021-01-14T14:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/\"},\"wordCount\":337,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/\",\"name\":\"Ceapro Inc. to Present at NobleCon17 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=\",\"datePublished\":\"2021-01-14T14:03:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceapro-inc-to-present-at-noblecon17\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ceapro Inc. to Present at NobleCon17\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ceapro Inc. to Present at NobleCon17 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/","og_locale":"en_US","og_type":"article","og_title":"Ceapro Inc. to Present at NobleCon17 - Market Newsdesk","og_description":"Live video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; Ceapro Inc.\u00a0(TSX-V: CZO; OTCQX: CRPOF) (\u201cCeapro\u201d or the \u201cCompany\u201d), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at NobleCon17 &#8211; Noble Capital Markets\u2019 Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 11:15 AM ET.\u00a0 A high-definition, video webcast will be available at the time of the Company\u2019s presentation for those registered to attend the event. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com. A &hellip; Continue reading \"Ceapro Inc. to Present at NobleCon17\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-14T14:03:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ceapro Inc. to Present at NobleCon17","datePublished":"2021-01-14T14:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/"},"wordCount":337,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/","name":"Ceapro Inc. to Present at NobleCon17 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=","datePublished":"2021-01-14T14:03:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTc0NyMzOTE4ODI0IzIwOTM4Mzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceapro-inc-to-present-at-noblecon17\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ceapro Inc. to Present at NobleCon17"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=414958"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414958\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=414958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=414958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=414958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}